Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2023-04-05 Regulatory Filings
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 5, 2023. It references the consummation of a business combination on March 20, 2023, and includes audited consolidated financial statements of Zura Bio Limited as of December 31, 2022, and for the period from inception to December 31, 2022, attached as Exhibit 99.1. The document itself is relatively short (3817 characters) and primarily serves to report the business combination event and attach the audited financial statements. Since the document is a Form 8-K filing reporting a significant event and attaching financial statements of a business acquired, it fits best under Regulatory Filings (RNS) as it is not a full Annual Report (10-K) or standalone Audit Report (AR) but a current report disclosing a material event with financial statements included as exhibits. The document does not contain a full annual report narrative or comprehensive financial analysis but is a regulatory disclosure of a business combination event with attached audited financials.
2023-04-05 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-04-04 English
SC 13G
Major Shareholding Notification
2023-04-04 English
Major Shareholding Notification 2023
Major Shareholding Notification
2023-03-31 English
PRIMARY DOCUMENT
Director's Dealing
2023-03-30 English
10-K
Annual Report FY 2022
2023-03-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.